Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases

• Published in: Journal der Deutschen Dermatologischen Gesellschaft Vol. 6; no. 5; pp. 366 - 373
• Main Authors: Hertl, Michael, Zillikens, Detlef, Borradori, Luca, Bruckner-Tuderman, Leena, Burckhard, Harald, Eming, Rüdiger, Engert, Andreas, Goebeler, Matthias, Hofmann, Silke, Hunzelmann, Nicolas, Karlhofer, Franz, Kautz, Ocko, Lippert, Undine, Niedermeier, Andrea, Nitschke, Martin, Pfütze, Martin, Reiser, Marcel, Rose, Christian, Schmidt, Enno, Shimanovich, Iakov, Sticherling, Michael, Wolff-Franke, Sonja
• Format: Journal Article Conference Proceeding
• Language: English; German
• Published: Oxford, UK Blackwell Publishing Ltd 01.05.2008
• Subjects: Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Murine-Derived; Autoantibody; Autoimmune Diseases - drug therapy; B lymphocyte; Bullous skin diseases; Dermatology - standards; Drug Administration Schedule; Humans; Immune suppression; Practice Guidelines as Topic; Rituximab; Skin Diseases, Vesiculobullous - drug therapy
• ISSN: 1610-0379; 1610-0387
• DOI: 10.1111/j.1610-0387.2007.06602.x

Summary Autoimmune bullous skin disorders are induced by autoantibodies against distinct adhesion complexes of the epidermal and dermal‐epidermal junction. Since most of these disorders are characterized by a severe, potentially lethal course,they require long‐term immunosuppressive treatment to reduce the de novo synthesis of pathogenic autoantibodies by B lymphocytes. Rituximab, a chimeric monoclonal antibody against CD20 on B lymphocytes, has shown promise in several case reports or cohort studies in the treatment of paraneo‐plastic pemphigus,refractory cases of pemphigus vulgaris and foliaceus and in other autoimmune bullous disorders.Treatment with rituximab leads to depletion of pathogenic B‐cells which may last up to 12 months resulting in a reduction of plasma cells secreting pathogenic autoantibodies.Rituximab is usually administered in an adjuvant setting at a dose of 375 mg/m2 i.v.in weekly intervals for four consecutive weeks in addition to the standard immunosuppressive treatment.The present consensus statement of German‐speaking derma‐tologists,rheumatologists and oncologists summarizes and evaluates the current evidence for the use and mode of application of rituximab in autoimmune bullous skin disorders.